"Polyisoprenyl Phosphates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phosphoric or pyrophosphoric acid esters of polyisoprenoids.
Descriptor ID |
D011106
|
MeSH Number(s) |
D02.455.849.690 D02.705.400.725
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Polyisoprenyl Phosphates".
Below are MeSH descriptors whose meaning is more specific than "Polyisoprenyl Phosphates".
This graph shows the total number of publications written about "Polyisoprenyl Phosphates" by people in this website by year, and whether "Polyisoprenyl Phosphates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
2006 | 1 | 1 | 2 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Polyisoprenyl Phosphates" by people in Profiles.
-
Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. Neuroscience. 2012 Jan 27; 202:1-9.
-
Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol. 2008 May; 73(5):1381-93.
-
Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma. FASEB J. 2008 Jan; 22(1):47-54.
-
Hydrophilic anilinogeranyl diphosphate prenyl analogues are Ras function inhibitors. Biochemistry. 2006 Dec 26; 45(51):15862-72.
-
Rho/ROCK pathway as a target of tumor therapy. J Neurosci Res. 2006 Feb 01; 83(2):243-55.
-
Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997 Dec 01; 100(11):2671-9.